Aditxt (NASDAQ:ADTX – Get Free Report) and Incannex Healthcare (NASDAQ:IXHL – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Aditxt and Incannex Healthcare, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Incannex Healthcare | 2 | 0 | 1 | 0 | 1.67 |
Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 692.95%. Given Incannex Healthcare’s stronger consensus rating and higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Aditxt.
Insider & Institutional Ownership
15.5% of Aditxt shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Aditxt has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7, suggesting that its share price is 600% more volatile than the S&P 500.
Profitability
This table compares Aditxt and Incannex Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Incannex Healthcare | N/A | -25.62% | -24.46% |
Earnings and Valuation
This table compares Aditxt and Incannex Healthcare”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.03 | -$41.71 million | ($100,788.35) | -0.00 |
| Incannex Healthcare | $90,000.00 | 316.54 | -$19.30 million | ($1.69) | -1.34 |
Incannex Healthcare has higher revenue and earnings than Aditxt. Incannex Healthcare is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Summary
Incannex Healthcare beats Aditxt on 12 of the 14 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Incannex Healthcare
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
